Cancer Clinical Trial
— POEMOfficial title:
A Pilot Study of a Mobile/Online-based Mindfulness Intervention for Cancer Patients and Caregivers
Verified date | December 2018 |
Source | Kaiser Permanente |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A cancer diagnosis is extremely stressful, emotionally challenging, and often life-altering
for both patients and their loved ones. Although more than one-third of patients experience
distress, doctors are typically at a loss as to how to help patients and their families
manage these emotional challenges. Mindfulness-based programs, including meditation, are
offered at major medical centers in the US and have been found to help reduce stress and
improve quality of life among cancer patients. However, these classes often require 30+ hours
of in-person instruction over 8 weeks, which is neither practical nor feasible for patients
undergoing chemotherapy due to side effects and scheduling conflicts.
This study will test whether an 8-week mobile app-based mindfulness program is accepted and
useful for patients who have recently received chemotherapy and their loved ones. It will
also test whether it is feasible to randomize participants into three groups: intervention,
active control (receiving progressive muscle relaxation through the same app) and a wait list
control group (will receive the meditation intervention 8 weeks later), so that a future
study can test whether mindfulness intervention can help reduce stress and improve quality of
life. Because many Americans own smartphone or tablet, an app that can teach stress reduction
techniques at home or at infusion clinics has great potential to address emotional needs that
providers often cannot.
The study will also include caregivers of patients who have recently received chemotherapy as
research has shown that caregivers tend to show high levels of stress and depression and
worse physical health compared to non-caregivers. The negative effects of caregiving are most
pronounced in caregivers of patients with cancer. However, little support is directed to
caregivers as most medical attention goes toward the patients. The patient-caregiver
relationship may serve as a source of mutual support and a surrogate for community, which is
traditionally considered to be an essential ingredient for sustaining mindfulness practices.
If this study is successful, it will justify a larger trial to determine if use of a
mindfulness app is effective in reducing stress and improving quality of life for cancer
patients and caregivers. If effective, this low-cost stress reduction strategy could be
distributed and used for all types and stages of cancer patients and their caregivers,
anywhere, any time, helping to improve the quality of life of the many individuals affected
by cancer.
Status | Completed |
Enrollment | 129 |
Est. completion date | November 8, 2018 |
Est. primary completion date | November 8, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - active member of Kaiser Permanente Northern California - a diagnosis of cancer, and currently undergoing chemotherapy or completed chemotherapy in the past 6 months at time of recruitment - English literacy/fluency, access to a smartphone, a tablet (e.g., iPad) or a computer with internet - Caregivers: a partner, other family member, or a close friend who identify him/herself as the patient's primary unpaid caregiver. English literacy/fluency, access to a smartphone, a tablet (e.g., iPad) or a computer with internet access Exclusion Criteria: - Deafness - severe mental illness - Hospital Anxiety and Depression Scale score <8 or >14 on either anxiety or depression scale (patient only) - current stress reduction practice |
Country | Name | City | State |
---|---|---|---|
United States | Kaiser Permanente Northern California | Oakland | California |
Lead Sponsor | Collaborator |
---|---|
Kaiser Permanente | American Cancer Society, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in anxiety and depression | The Hospital Anxiety and Depression Scale (HADS) will be used to measure both anxiety and depression. This scale is frequently used to assess psychosocial outcomes in cancer patients. The HADS is a 14-item self-report measurement tool designed for use in medical outpatient settings to assess depression and anxiety. Each subscale is scored from 0 to 21, with higher scores indicating greater distress; 0-7 is generally considered "normal," 8-10 "mild," 11-14 "moderate," and 15-21 "severe" symptoms. | Baseline to 8 weeks | |
Primary | Change in anxiety and depression | The Hospital Anxiety and Depression Scale (HADS) will be used to measure both anxiety and depression. This scale is frequently used to assess psychosocial outcomes in cancer patients. The HADS is a 14-item self-report measurement tool designed for use in medical outpatient settings to assess depression and anxiety. Each subscale is scored from 0 to 21, with higher scores indicating greater distress; 0-7 is generally considered "normal," 8-10 "mild," 11-14 "moderate," and 15-21 "severe" symptoms. | Baseline to 16 weeks | |
Secondary | Change in distress | The National Comprehensive Cancer Network Distress Thermometer will be used to assess current distress level. Respondents are asked to rate their level of distress during the past week by circling a number on an image of a thermometer, with 0 indicating "no distress" and 10 "extreme distress". | Baseline to 8 weeks | |
Secondary | Change in distress | The National Comprehensive Cancer Network Distress Thermometer will be used to assess current distress level. Respondents are asked to rate their level of distress during the past week by circling a number on an image of a thermometer, with 0 indicating "no distress" and 10 "extreme distress". | Baseline to 16 weeks | |
Secondary | Change in fatigue | The Brief Fatigue Inventory assesses the severity and impact of cancer-related fatigue, asks about current level of fatigue, average and worst level of fatigue in the past 24 hours, and extent to which fatigue interfered with various aspects of life in the past 24 hours (e.g., mood, walking ability) on a 10-point Likert scale. A global fatigue score is calculated by averaging all items (ranging from 0 to 10). A higher score represents greater severity and impact of fatigue. | Baseline to 8 weeks | |
Secondary | Change in fatigue | The Brief Fatigue Inventory assesses the severity and impact of cancer-related fatigue, asks about current level of fatigue, average and worst level of fatigue in the past 24 hours, and extent to which fatigue interfered with various aspects of life in the past 24 hours (e.g., mood, walking ability) on a 10-point Likert scale. A global fatigue score is calculated by averaging all items (ranging from 0 to 10). A higher score represents greater severity and impact of fatigue. | Baseline to 16 weeks | |
Secondary | Change in Pain | The Patient-Reported Outcomes Measurement Information System(PROMIS) pain scale will be used to measure the self-reported consequences of pain on relevant aspects of one's life. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. | Baseline to 8 weeks | |
Secondary | Change in Pain | The Patient-Reported Outcomes Measurement Information System(PROMIS) pain scale will be used to measure the self-reported consequences of pain on relevant aspects of one's life. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. | Baseline to 16 weeks | |
Secondary | Change in sleep quality | The Patient-Reported Outcomes Measurement Information System(PROMIS) Sleep-Related Impairment scale measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. | Baseline to 8 weeks | |
Secondary | Change in sleep quality | The Patient-Reported Outcomes Measurement Information System(PROMIS) Sleep-Related Impairment scale measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. | Baseline to 16 weeks | |
Secondary | Change in mindfulness | Mindfulness will be measured using the Five Facet Mindfulness Questionnaire | Baseline to 8 weeks | |
Secondary | Change in mindfulness | Mindfulness will be measured using the Five Facet Mindfulness Questionnaire | Baseline to 16 weeks | |
Secondary | Change in Post Traumatic Growth | Self-reported posttraumatic growth as a result of having cancer will be measured using the Post Traumatic Growth Inventory. | Baseline to 8 weeks | |
Secondary | Change in Post Traumatic Growth | Self-reported posttraumatic growth as a result of having cancer will be measured using the Post Traumatic Growth Inventory. | Baseline to 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|